Alto Neuroscience ANRO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -38.9%+2.9pp | -41.8%+3.2pp | -45%-2.2pp | -42.8%-4.7pp | -38%— | |
| Return on assets | -33.2%+1.8pp | -34.9%+1.9pp | -36.8%-0.3pp | -36.5%-3.4pp | -33.1%+13.4pp | |
| Liquidity | ||||||
| Current ratio | 20.5×+4.8× | 15.7×+0.3× | 15.4×-3.0× | 18.4×-4.1× | 22.5×+5.6× | |
| Quick ratio | 20.5×+4.8× | 15.7×+0.3× | 15.4×-3.0× | 18.4×-4.1× | 22.5×+5.6× | |
| Cash ratio | 20.1×+4.5× | 15.6×+0.3× | 15.3×-2.9× | 18.2×-4.0× | 22.2×+5.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.1×+0.1× | |
| Interest coverage | -32.2×-5.3× | -26.9×+2.9× | -29.8×+6.7× | -36.5×+6.5× | -43×+6.9× | |
| Per Share | ||||||
| Book value per share | $7.40+41.2% | $5.24+27.3% | $4.12-9.7% | $4.56-11.4% | $5.14-16.5% | |
| Valuation | ||||||
| Market capitalization | $874.19M+1,358% | $552.98M+408% | $108.85M+60.8% | $67.68M+15.7% | $58.48M-48.7% | |
| Enterprise value | $630.81M-958% | $397.73M+9,872% | -$4.07M+92.6% | -$55.1M+29.0% | -$77.55M-98.8% | |
| Price / book | 3.6×+3.2× | 3.7×+2.7× | 1×+0.4× | 0.5×+0.1× | 0.4×-0.3× | |
| Free cash flow yield | -7.1%+83.0pp | -9.4%+40.1pp | -49.4%+34.2pp | -83.7%+10.2pp | -93.8%-50.4pp | |
| Earnings yield | -8.4%+95.4pp | -11.4%+45.8pp | -57.2%+38.6pp | -95.8%+12.2pp | -108%-54.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Alto Neuroscience's ratios come from?
- Every ratio is computed from Alto Neuroscience's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.